Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia

S S Kang1, P W Wong

  • 1Department of Pediatrics, Rush Medical College and Rush-Presbyterian St. Luke's Medical Center, Chicago, IL 60612, USA.

Atherosclerosis
|January 26, 1996
PubMed

Insights

Assessing vascular disease risk requires demonstrating overt hyperhomocyst(e)inemia. Identifying genetic defects is crucial alongside plasma homocyst(e)ine levels for accurate risk evaluation.

Area of Science:

  • Biochemistry
  • Genetics
  • Cardiovascular Medicine

Background:

  • Hyperhomocysteinemia is linked to vascular disease.
  • Genetic defects can cause persistent hyperhomocysteinemia.
  • Nongenetic factors can influence hyperhomocysteinemia expression.

Purpose of the Study:

  • To evaluate the risk of vascular disease associated with hyperhomocysteinemia.
  • To emphasize the importance of identifying genetic defects in hyperhomocysteinemia assessment.
  • To explore methods for evaluating hyperhomocysteinemia in the context of vascular disease risk.

Main Methods:

  • Demonstrating overt hyperhomocysteinemia.
  • Investigating genetic defects (e.g., cystathionine synthase deficiency, methylenetetrahydrofolate reductase).
  • Utilizing post-methionine homocyst(e)ine determination when genetic defects are not found.

Main Results:

  • Clinical vascular disease in nonhomocystinuric subjects requires prolonged hyperhomocysteinemia, often linked to genetic defects.
  • Plasma homocyst(e)ine concentration alone may be insufficient due to nongenetic factor interference.
  • Genetic analysis is as vital as plasma homocyst(e)ine measurement for risk assessment.

Conclusions:

  • Accurate assessment of hyperhomocyst(e)inemia-associated vascular disease risk necessitates identifying underlying genetic defects.
  • Post-methionine homocyst(e)ine levels can identify genetic susceptibility when environmental factors are controlled.
  • A combined approach of genetic screening and biochemical analysis is recommended for comprehensive risk evaluation.

Related Concept Videos

Multiple Allele Traits02:19

Multiple Allele Traits

For the same gene multiple alleles can interact to influence phenotypes like the shape and protein composition of an individual cells.By studying allele interactions on the molecular and cellular levels researchers can understand the resulting phenotypes and complications of human conditions like sickle cell trait, improving treatment.The ABO blood group system is a common example of multiple alleles in humans. This system includes three alleles called IA, IB, and i alleles, which combine in...
Translation01:37

Translation

Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.Translation Produces the Building Blocks of LifeProteins are called the...
Factors Affecting Erythropoiesis01:24

Factors Affecting Erythropoiesis

The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...